Literature DB >> 24533271

Worm therapy: How would you like your medicine?

David I Pritchard1.   

Abstract

Parasite immunologists have contributed significantly to our understanding of the human immune system, to the extent that live parasites are being tested as investigational medicinal products (IMPs) and their secretions are being analysed for potentially novel and effective immune regulatory molecules (IRMs). This article expresses an opinion on the current status of research, and suggests that parasite immunologists and the pharmaceutical industry combine to source non-immunogenic IRMs from parasites selected for their immune modulatory potential. The article also suggests that parasite immunologists should be perhaps more rigorous in their choice of infection and disease models in rodents.

Entities:  

Keywords:  Drug; Immune modulation; Industry; Parasite

Year:  2012        PMID: 24533271      PMCID: PMC3862429          DOI: 10.1016/j.ijpddr.2012.02.001

Source DB:  PubMed          Journal:  Int J Parasitol Drugs Drug Resist        ISSN: 2211-3207            Impact factor:   4.077


  12 in total

Review 1.  Parasitic worm therapy for allergy: is this incongruous or avant-garde medicine?

Authors:  D I Pritchard; D G Blount; P Schmid-Grendelmeier; S J Till
Journal:  Clin Exp Allergy       Date:  2011-12-14       Impact factor: 5.018

2.  Trichuris suis might be effective in treating allergic rhinitis.

Authors:  Robert W Summers; David E Elliott; Joel V Weinstock
Journal:  J Allergy Clin Immunol       Date:  2010-02-11       Impact factor: 10.793

Review 3.  Helminth-derived immunomodulators: can understanding the worm produce the pill?

Authors:  William Harnett; Margaret M Harnett
Journal:  Nat Rev Immunol       Date:  2010-03-12       Impact factor: 53.106

4.  Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study.

Authors:  J O Fleming; A Isaak; J E Lee; C C Luzzio; M D Carrithers; T D Cook; A S Field; J Boland; Z Fabry
Journal:  Mult Scler       Date:  2011-03-03       Impact factor: 6.312

5.  Iatrogenic Trichuris suis infection in a patient with Crohn disease.

Authors:  Richard L Kradin; Kamran Badizadegan; Pavan Auluck; Joshua Korzenik; Gregory Y Lauwers
Journal:  Arch Pathol Lab Med       Date:  2006-05       Impact factor: 5.534

Review 6.  Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.

Authors:  Adnan R Khan; Simon J Dovedi; Robert W Wilkinson; David I Pritchard
Journal:  Int Rev Immunol       Date:  2010-10       Impact factor: 5.311

7.  Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial.

Authors:  Robert W Summers; David E Elliott; Joseph F Urban; Robin A Thompson; Joel V Weinstock
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

8.  Heligmosomoides polygyrus immunomodulatory factor (IMF), targets T-lymphocytes.

Authors:  G Telford; D J Wheeler; P Appleby; J G Bowen; D I Pritchard
Journal:  Parasite Immunol       Date:  1998-12       Impact factor: 2.280

9.  Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-β pathway.

Authors:  John R Grainger; Katie A Smith; James P Hewitson; Henry J McSorley; Yvonne Harcus; Kara J Filbey; Constance A M Finney; Edward J D Greenwood; David P Knox; Mark S Wilson; Yasmine Belkaid; Alexander Y Rudensky; Rick M Maizels
Journal:  J Exp Med       Date:  2010-09-27       Impact factor: 14.307

10.  Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Peter Bager; John Arnved; Steen Rønborg; Jan Wohlfahrt; Lars K Poulsen; Tine Westergaard; Henning Willads Petersen; Bjarne Kristensen; Stig Thamsborg; Allan Roepstorff; Christian Kapel; Mads Melbye
Journal:  J Allergy Clin Immunol       Date:  2009-10-03       Impact factor: 10.793

View more
  1 in total

1.  Worming our way closer to the clinic.

Authors:  Matthew R Hepworth; Susanne Hartmann
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-07-15       Impact factor: 4.077

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.